GlassScriptPhysician profile
Klara Briskin
NPI 1518127174
$46,177.35
in general payments reported to CMS, 2019-2025
52 companies · $1,683 in 2025
The $1,683 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,590 · 2020: $3,949 · 2021: $12K · 2022: $14K · 2023: $9,850 · 2024: $2,954 · 2025: $1,683.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,596 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,800 · Education: $91.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,595.69 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,800.00 |
| Education | $91.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $18,786.35 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Biohaven Pharmaceutical Holding Company LTD. | $7,625.22 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $4,297.22 | 2020-2021 | |
| Allergan, INC. | $3,883.67 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $1,976.77 | 2019-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Pfizer INC. | $1,318.29 | 2019-2025 | |
| Mdd US Operations, LLC | $940.09 | 2019-2025 | Apokyn, Apokyn, Xadago |
| Lilly USA, LLC | $795.75 | 2019-2024 | Emgality, Reyvow |
| Amneal Pharmaceuticals LLC | $567.14 | 2021-2025 | Rytary, Crexont, Ongentys 50mg Capsules 30 |
| Scilex Pharmaceuticals INC. | $532.28 | 2022-2025 | Ztlido |
| Amgen INC. | $425.43 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $340.79 | 2019-2022 | |
| Upsher-Smith Laboratories LLC | $337.05 | 2019-2023 | |
| Lundbeck LLC | $283.69 | 2020-2025 | Rexulti, Vyepti |
| Takeda Pharmaceuticals U.S.A., INC. | $275.90 | 2020-2025 | Trintellix |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Klara Briskin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.